amrinone has been researched along with Thrombopenia in 14 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results demonstrate possible contribution of the enhancing effects of acetylamrinone on platelet aggregation occurring under blood flow conditions, which reduced the platelet count when occurring in real circulation, to the higher incidence of thrombocytopenia in patients treated with amrinone." | 7.72 | Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone. ( Goto, S; Handa, S; Hoshiba, Y; Ikeda, Y; Kumagai, A; Sadiq, A; Tamura, N; Tanabe, T; Yoshida, M, 2003) |
| "Amrinone-associated thrombocytopenia is thought to result from nonimmune-mediated peripheral platelet destruction." | 7.68 | Amrinone-associated thrombocytopenia: pharmacokinetic analysis. ( Allen-Webb, EM; McGough, EC; Pappas, JB; Ross, MP, 1993) |
| "The incidence of amrinone-induced thrombocytopenia has been reported to be 2." | 7.68 | Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone. ( Burnette, PK; Manny, RP; Mattingly, PM; Weston, MW, 1990) |
| "The frequency and characteristics of thrombocytopenia resulting from administration of amrinone, a new inotropic and vasodilator agent, was evaluated in 43 patients." | 7.67 | Amrinone-induced thrombocytopenia. ( Ansell, J; Benotti, JR; McCue, J; Parrilla, N; Tiarks, C, 1984) |
| "A patient with severe cardiac failure due to idiopathic congestive cardiomyopathy resistant to conventional therapy, responded to amrinone, a new non-glycosidic non-catecholamine positive inotropic agent." | 7.66 | Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure. ( Barrett, PA; Chong, B; Lvoff, R; Robinson, PJ, 1981) |
| "Amrinone is a new positive inotropic agent available in oral and intravenous preparations." | 6.66 | [Effects of amrinone administered orally and by injection in heart failure]. ( Bounhoure, JP; Calazel, J; Massabuau, P; Miquel, JP; Puel, J, 1985) |
| "Clinical trials of intravenous amrinone were performed in 462 patients severely ill with congestive heart failure." | 5.05 | Clinical safety of intravenous amrinone--a review. ( Treadway, G, 1985) |
| "Our results demonstrate possible contribution of the enhancing effects of acetylamrinone on platelet aggregation occurring under blood flow conditions, which reduced the platelet count when occurring in real circulation, to the higher incidence of thrombocytopenia in patients treated with amrinone." | 3.72 | Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone. ( Goto, S; Handa, S; Hoshiba, Y; Ikeda, Y; Kumagai, A; Sadiq, A; Tamura, N; Tanabe, T; Yoshida, M, 2003) |
| "Amrinone-associated thrombocytopenia is thought to result from nonimmune-mediated peripheral platelet destruction." | 3.68 | Amrinone-associated thrombocytopenia: pharmacokinetic analysis. ( Allen-Webb, EM; McGough, EC; Pappas, JB; Ross, MP, 1993) |
| "The incidence of amrinone-induced thrombocytopenia has been reported to be 2." | 3.68 | Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone. ( Burnette, PK; Manny, RP; Mattingly, PM; Weston, MW, 1990) |
| "The frequency and characteristics of thrombocytopenia resulting from administration of amrinone, a new inotropic and vasodilator agent, was evaluated in 43 patients." | 3.67 | Amrinone-induced thrombocytopenia. ( Ansell, J; Benotti, JR; McCue, J; Parrilla, N; Tiarks, C, 1984) |
| "Amrinone is a cardiotonic agent associated with reversible thrombocytopenia in 20% to 50% of patients." | 3.67 | Effect of oral amrinone on platelet function and survival. ( Brandt, JT; Hermiller, J; Leier, CV; Miller, L; Unverferth, DV, 1984) |
| "We gave intravenous amrinone to 40 patients in heart failure, and oral amrinone to 18 patients." | 3.66 | Side effects of amrinone therapy. ( Webb-Peploe, MM; Wilsmhurst, PT, 1983) |
| "A patient with severe cardiac failure due to idiopathic congestive cardiomyopathy resistant to conventional therapy, responded to amrinone, a new non-glycosidic non-catecholamine positive inotropic agent." | 3.66 | Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure. ( Barrett, PA; Chong, B; Lvoff, R; Robinson, PJ, 1981) |
| "Amrinone is a new positive inotropic agent available in oral and intravenous preparations." | 2.66 | [Effects of amrinone administered orally and by injection in heart failure]. ( Bounhoure, JP; Calazel, J; Massabuau, P; Miquel, JP; Puel, J, 1985) |
| " Adverse effects are minimal, with dosage limited predominantly by decreases in filling pressures." | 2.37 | Intravenous use of amrinone for the treatment of the failing heart. ( LeJemtel, T; Mancini, D; Sonnenblick, E, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (78.57) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sadiq, A | 1 |
| Tamura, N | 1 |
| Yoshida, M | 1 |
| Hoshiba, Y | 1 |
| Kumagai, A | 1 |
| Tanabe, T | 1 |
| Handa, S | 1 |
| Ikeda, Y | 1 |
| Goto, S | 1 |
| MacGillivray, RG | 1 |
| Shama, DM | 1 |
| Kinney, EL | 1 |
| Ballard, JO | 1 |
| Carlin, B | 1 |
| Zelis, R | 1 |
| Ansell, J | 1 |
| Tiarks, C | 1 |
| McCue, J | 1 |
| Parrilla, N | 1 |
| Benotti, JR | 1 |
| Brandt, JT | 1 |
| Miller, L | 1 |
| Hermiller, J | 1 |
| Unverferth, DV | 1 |
| Leier, CV | 1 |
| Wilsmhurst, PT | 1 |
| Webb-Peploe, MM | 1 |
| Robinson, PJ | 1 |
| Lvoff, R | 1 |
| Chong, B | 1 |
| Barrett, PA | 1 |
| Weber, KT | 1 |
| Andrews, V | 1 |
| Janicki, JS | 1 |
| Wilson, JR | 1 |
| Fishman, AP | 1 |
| Ross, MP | 1 |
| Allen-Webb, EM | 1 |
| Pappas, JB | 1 |
| McGough, EC | 1 |
| Mattingly, PM | 1 |
| Burnette, PK | 1 |
| Weston, MW | 1 |
| Manny, RP | 1 |
| Mancini, D | 1 |
| LeJemtel, T | 1 |
| Sonnenblick, E | 1 |
| Tommaso, CL | 1 |
| Treadway, G | 1 |
| Bounhoure, JP | 1 |
| Massabuau, P | 1 |
| Puel, J | 1 |
| Miquel, JP | 1 |
| Calazel, J | 1 |
2 reviews available for amrinone and Thrombopenia
| Article | Year |
|---|---|
Intravenous use of amrinone for the treatment of the failing heart.
Topics: Aminopyridines; Amrinone; Cardiac Complexes, Premature; Cardiac Output; Cardiotonic Agents; Drug Int | 1985 |
Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Arrhythmias, Cardiac; Calcium; Cardiac Output; Cardi | 1986 |
2 trials available for amrinone and Thrombopenia
| Article | Year |
|---|---|
Clinical safety of intravenous amrinone--a review.
Topics: Aminopyridines; Amrinone; Arrhythmias, Cardiac; Cardiotonic Agents; Clinical Trials as Topic; Drug I | 1985 |
[Effects of amrinone administered orally and by injection in heart failure].
Topics: Administration, Oral; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Clinical Trials as Topic; | 1985 |
10 other studies available for amrinone and Thrombopenia
| Article | Year |
|---|---|
Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Amrinone; Cyclic Nucleotide Phosphodiesterases, Type 3; | 2003 |
Amrinone, platelets, and the balloon pump.
Topics: Amrinone; Blood Platelets; Cardiac Output, Low; Cardiotonic Agents; Coronary Artery Bypass; Drug The | 1988 |
Amrinone-mediated thrombocytopenia.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Platelet Count; Thrombocytopeni | 1983 |
Amrinone-induced thrombocytopenia.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Platelets; Dose-Response Relationship, Drug; Female; He | 1984 |
Effect of oral amrinone on platelet function and survival.
Topics: Administration, Oral; Adult; Aminopyridines; Amrinone; Blood Platelets; Cardiotonic Agents; Cell Sur | 1984 |
Side effects of amrinone therapy.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Female; Heart Failu | 1983 |
Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Hemodynamics; Hum | 1981 |
Amrinone and exercise performance in patients with chronic heart failure.
Topics: Aminopyridines; Amrinone; Chronic Disease; Exercise Test; Female; Heart Failure; Hemodynamics; Human | 1981 |
Amrinone-associated thrombocytopenia: pharmacokinetic analysis.
Topics: Amrinone; Child; Child, Preschool; Humans; Infant; Metabolic Clearance Rate; Platelet Count; Risk Fa | 1993 |
Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone.
Topics: Amrinone; Bone Marrow; Dopamine; Heart Failure; Humans; Hypotension; Infusions, Intravenous; Male; M | 1990 |